Oncoinvent CEO Jan A. Alfheim will be presenting at 10:25 during the morning Venture Session on Thursday the 14th of December

Press Release 08.2017: Oncoinvent held an opening ceremony for its new production and lab facilities today. A total of 40 guests attended the opening.

Press Release: Oncoinvent announced today that European Patent 3111959 entitled ”Radiotherapeutic particles and suspensions” has issued. This patent provides patent protection for the company’s lead product candidate Radspherin® in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Press Release 06.2017

Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients.
In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention.
The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.

Researchers Sara Westrøm and Elisa Napoli will each be presenting findings of their research during the morning session on Sunday the 22nd of October

Oncoinvent CEO Jan A. Alfheim speaks with Radforsk’s Jónas Einarsson and Elisabeth Kirkeng Andersen

Press Release 05.2017: Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials.

Press Release 04.2017: Key positions to assist in the development and commercialization of Radspherin® have been filled, bringing valuable expertise and experience to the company

The poster ‘Preclinical Evaluation of a Novel Alpha-Particle Emitting Therapeutic Agent for Intraperitoneal Therapy of Peritoneal Metastases’ by Oncoinvent scientists Tina B. Bønsdorff, Sara Westrøm, Øyvind S. Bruland and Roy H. Larsen will be presented at the congress.

CEO Jan A. Alfheim will give a company presentation at the upcoming Partnership4Life symposium on February 15.

Jan Alan Alfheim

Chief Executive Officer


+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.